| ²é¿´: 1273 | »Ø¸´: 7 | ||
| µ±Ç°Ö»ÏÔʾÂú×ãÖ¸¶¨Ìõ¼þµÄ»ØÌû£¬µã»÷ÕâÀï²é¿´±¾»°ÌâµÄËùÓлØÌû | ||
cclz110Òø³æ (СÓÐÃûÆø)
|
[ÇóÖú]
¹ØÓÚolaparibÔÚÖйúµÄ״̬ ÒÑÓÐ1È˲ÎÓë
|
|
|
¸÷λ³æÓÑ£¬ÎÒÔÚthomasÉϲ鵽olaparibÔÚÖйúµÄ״̬ÈçÏ£º CHINA OVARIAN CANCER In January 2011, AstraZeneca planned a regulatory filing in an undisclosed emerging market in 2016 [1164174]. In February 2014, a filing in China for BRCAm PSR ovarian cancer was expected in 2016 [1522992]. In December 2013, a Chinese filing for 1st-line BRCAm ovarian cancer was expected in 2017 [1515365]. In June 2014, filing for 1st-line BRCAm ovarian cancer was expected in 2018 [1581975]. ÕâÊÇÖ¸ÔÚ2013ÄêÒѾÌá½»ÉêÇëÁË£¬»¹ÊÇ×¼±¸ÔÚ2017ÄêÌá½»ÉêÇ룬ÁíÍâÔõôÔÚCDEÍøÕ¾Éϲéѯ´ËÀàÐÅÏ¢£¬ÎÒÊǵǼCDEÍøÕ¾ºó½øÈëÒÑÓÐÅú×¼ÎĺźÍÔÚÉóÐÅÏ¢²éѯһÀ¸ÊäÈ뻯ºÏÎïÃû³Æ£ºolaparib»òÕßÖÐÎÄÃû³Æ°ÂÀÅÁÄᣬËÑË÷½á¹ûÏÔʾΪ0£¬ÊÇÎÒûÕÒ¶Ô·½·¨£¬»¹ÊÇÆäËûÔÒò£¬²ËÄñÒ»¸ö£¬Çë½Ì¸÷λÀ²¡£ |
» ²ÂÄãϲ»¶
SPguide®£ºÐ¡ÊóÌåÄÚÆ¢ÔàתȾµÄÒ»¼ü½â¾ö·½°¸
ÒѾÓÐ0È˻ظ´
¸ßЧ·Î°ÐÏòRNAתȾ£¬¼ÓËٷβ¿RNAÒ©Î↑·¢
ÒѾÓÐ2È˻ظ´
Ò©ÎïѧÂÛÎÄÈóÉ«/·ÒëÔõôÊÕ·Ñ?
ÒѾÓÐ190È˻ظ´
¶þÌǵÄÌÇÖ¬£¬ºÏ³Éºósephadex LH-20·ÖÀë²»³öÀ´£¬ÇóÖú
ÒѾÓÐ1È˻ظ´
ÄÏ·½Ò½¿Æ´óѧÖé½Ò½ÔºÐ¤¼ÆÉú¿ÎÌâ×éÕÐÊÕ²©Ê¿Éú £¨2026ÄêÈëѧ£©
ÒѾÓÐ2È˻ظ´
349ҩѧר˶105500Çóµ÷¼Á
ÒѾÓÐ0È˻ظ´
Çóµ÷¼Á
ÒѾÓÐ1È˻ظ´
298Çóµ÷¼ÁÒ»Ö¾Ô¸Öк£Ñó
ÒѾÓÐ3È˻ظ´
ҩѧµ÷¼ÁÉêÇë×Ô¼öÐÅ£¬Ò»Ö¾Ô¸ÖÐÄÏ´óѧ
ÒѾÓÐ1È˻ظ´
ҩѧ349ר˶Çóµ÷¼Á
ÒѾÓÐ1È˻ظ´
¡¶×óÒÒÀÎ÷̹עÉäÒºÖÆ±¸¹¤ÒÕÑо¿¡¢ÖÊÁ¿¿ØÖƺÍÎȶ¨ÐÔÑо¿¡·ÏÂÔØ
ÒѾÓÐ1È˻ظ´
» ±¾Ö÷ÌâÏà¹Ø¼ÛÖµÌùÍÆ¼ö£¬¶ÔÄúͬÑùÓаïÖú:
Öйú¿ÆÑ§GÓ¢ÎİæÒѾµ½ÁËAwaiting AE Recommendation״̬ÁË£¬Á½ÌìÁË£¬½ôÕż¤¶¯£¡
ÒѾÓÐ4È˻ظ´
Öйúũҵ¿ÆÑ§Ó¢ÎÄͶ¸å״̬ Awaiting DIR Recommendation ÊÇʲôÒâ˼
ÒѾÓÐ10È˻ظ´
ÇëÎÊÔÚÖйú»·¾³¿ÆÑ§Í¶¸åһƪ£¬¸å¼þ״̬Ϊ½ÓÊÕ ÊÇÒѾ¼ÓÃÁËÂð£¿
ÒѾÓÐ14È˻ظ´
Öйú¿ÆÑ§Ð¡ÐÞºóÖØÍ¶ ״̬Awaiting ED Processing³ÖÐø¶à¾Ã
ÒѾÓÐ15È˻ظ´
ÔÚÖйúÎïÁ÷ѧÊõÄê»áͶÁËһƪÂÛÎÄ£¬ÂÛÎÄ״̬ÏÔʾÒÑÉóºË£¬ÊÇʲôÒâ˼°¡£¿
ÒѾÓÐ6È˻ظ´
Öйúµç»ú¹¤³Ìѧ±¨£¬ÓÐÒ»¸öÍâÉóµ±Ìì»ØÀ´ÁË£¬Ã»ÓÐÉó¸åÒâ¼û£¬ÎÄÕÂ״̬»¹ÊÇÍâÉóÖÐ
ÒѾÓÐ24È˻ظ´
¡¶ÖйúÎÀÉú¾¼Ã¡·Í¶¸åÒ»¸ö¶àÔ£¬´Ó³õÉó±äΪ¸´Éó£¬ÇëÎÊÏÖÔÚÊÇʲô״̬£¬ºóÐøÄØ
ÒѾÓÐ6È˻ظ´
ÖйúÓÐÉ«½ðÊôͶ¸å״̬һֱΪÍËÐÞ£¡£¡£¡£¡
ÒѾÓÐ3È˻ظ´
ÖйúÎïÀíB ״̬±ä»¯£¬ÕâÊÇʲôÇé¿ö£¿
ÒѾÓÐ8È˻ظ´
Öйú»úе¹¤³Ì¸å¼þ״̬Ö÷±àÉ󣬻¹ÓÐÏ£ÍûÂð£¿
ÒѾÓÐ11È˻ظ´
Ͷ¸åÖйú¿ÆÑ§Ó¢Îİ棨G¼£©Í¶¸å״̬ÎÊÌâ
ÒѾÓÐ8È˻ظ´
Çë½Ì£º¡¶Öйú»¯Ñ§¹¤³Ìѧ±¨¡·Éó¸å¹ý³ÌÖеġ°ËÍÐÞÓ¢ÎÄ¡±ÊÇʲô״̬£¿
ÒѾÓÐ7È˻ظ´
Öйú¿ÆÑ§Éó¸å״̬
ÒѾÓÐ27È˻ظ´
¹ØÓÚÖйú¿ÆÑ§¡°Éú²úÖС±ÊÇʲô״̬£¿
ÒѾÓÐ21È˻ظ´
ÖйúÓʵç¸ßУѧ±¨£¨Ó¢Îİ棩"±à¼¼Ó¹¤¡°×´Ì¬¡±Î¬³Ö¶à¾Ã°¡£¿
ÒѾÓÐ7È˻ظ´
ÖйúÓʵç¸ßУѧ±¨£¨Ó¢Îİ棩¼ÓÃÍËÐÞºó״̬ºóµÄÏÂÒ»½×¶ÎÊÇʲô?
ÒѾÓÐ11È˻ظ´
Öйú»·¾³¿ÆÑ§Í¶¸å״̬
ÒѾÓÐ6È˻ظ´
Lyell_Ȣ
гæ (СÓÐÃûÆø)
- Ó¦Öú: 15 (СѧÉú)
- ½ð±Ò: 819.2
- ºì»¨: 1
- Ìû×Ó: 100
- ÔÚÏß: 54.1Сʱ
- ³æºÅ: 2009907
- ×¢²á: 2012-09-18
- ÐÔ±ð: GG
- רҵ: ÖÐÒ©ÖÆ¼Á
7Â¥2014-09-18 10:35:09
wjswift
ÖÁ×ðľ³æ (Ö°Òµ×÷¼Ò)
¿´ÎÄÏ×£¬×öʵÑé......
- DRDEPI: 1
- Ó¦Öú: 33 (СѧÉú)
- ¹ó±ö: 1.131
- ½ð±Ò: 15527.4
- É¢½ð: 20
- ºì»¨: 33
- Ìû×Ó: 3911
- ÔÚÏß: 694.8Сʱ
- ³æºÅ: 112270
- ×¢²á: 2005-11-21
¡¾´ð°¸¡¿Ó¦Öú»ØÌû
¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï
¸Ðл²ÎÓ룬ӦÖúÖ¸Êý +1
cclz110: ½ð±Ò+10, ¡ï¡ï¡ï¡ï¡ï×î¼Ñ´ð°¸ 2014-09-16 20:46:55
¸Ðл²ÎÓ룬ӦÖúÖ¸Êý +1
cclz110: ½ð±Ò+10, ¡ï¡ï¡ï¡ï¡ï×î¼Ñ´ð°¸ 2014-09-16 20:46:55

2Â¥2014-09-16 19:53:18
cclz110
Òø³æ (СÓÐÃûÆø)
- Ó¦Öú: 0 (Ó×¶ùÔ°)
- ½ð±Ò: 924.6
- É¢½ð: 3
- ºì»¨: 1
- Ìû×Ó: 246
- ÔÚÏß: 35.9Сʱ
- ³æºÅ: 382830
- ×¢²á: 2007-05-25
- ÐÔ±ð: GG
- רҵ: ¸ß·Ö×ÓÎïÀíÓë¸ß·Ö×ÓÎïÀí»¯
3Â¥2014-09-16 20:46:57
cclz110
Òø³æ (СÓÐÃûÆø)
- Ó¦Öú: 0 (Ó×¶ùÔ°)
- ½ð±Ò: 924.6
- É¢½ð: 3
- ºì»¨: 1
- Ìû×Ó: 246
- ÔÚÏß: 35.9Сʱ
- ³æºÅ: 382830
- ×¢²á: 2007-05-25
- ÐÔ±ð: GG
- רҵ: ¸ß·Ö×ÓÎïÀíÓë¸ß·Ö×ÓÎïÀí»¯
4Â¥2014-09-16 20:49:21













»Ø¸´´ËÂ¥